Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays

Emily R Adams; Rekha Anand; Monique I Andersson; Kathryn Auckland; J Kenneth Baillie; Eleanor Barnes; John Bell; Tamsin Berry; Sagida Bibi; Miles Carroll; Senthil Chinnakannan; Elizabeth Clutterbuck; Richard J Cornall; Derrick W Crook; Thushan De Silva; Wanwisa Dejnirattisai; Kate E Dingle; Christina Dold; David W Eyre; Helen Farmer; Sarah J Hoosdally; Alistair Hunter; Katie Jeffrey; Paul Klenerman; Julian Knight; Clarice Knowles; Andrew J Kwok; Ullrich Leuschner; Chang Liu; Cesar Lopez-Camacho; Philippa C Matthews; Hannah McGivern; Alexander J Mentzer; Jonathan Milton; Juthathip Mongkolsapaya; Shona C Moore; Marta S Oliveira; Fiona Pereira; Timothy Peto; Rutger J Ploeg; Andrew Pollard; Tessa Prince; David J Roberts; Justine K Rudkin; Gavin R Screaton; Malcolm G Semple; Donal T Skelly; Elliot Nathan Smith; Julie Staves; David Stuart; Piyada Supasa; Tomas Surik; Pat Tsang; Lance Turtle; A Sarah Walker; Beibei Wang; Charlotte Washington; Nicholas Watkins; James Whitehouse; Sally Beer; Robert Levin; Alexis Espinosa; Dominique Georgiou; Jose Carlos Martinez Garrido; Hannah Thraves; Elena Perez Lopez; Maria del Rocio Fernandez Mendoza; Alberto Jose Sobrino Diaz; Veronica Sanchez

We tested LFIA devices designed to detect IgM, IgG or total antibodies to SARS-CoV-2 produced by nine manufacturers short-listed as a testing priority by the UK Government Department of Health and Social Care (DHSC), based on appraisals of device provenance and available performance data. Individual manufacturers did not approve release of device-level data, so device names are anonymised.